In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $16.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sam Slutsky has given his Buy rating due to a combination of factors tied to the encouraging EP-104GI data in eosinophilic esophagitis and the company’s solid financial position. The highest-dose cohort in the Phase 1b/2a study showed durable symptom relief out to 36 weeks that is consistent with clinical remission thresholds, alongside marked improvement in tissue measures and the largest reduction in peak eosinophil counts among tested cohorts, suggesting meaningful and sustained biological activity.
When these results are viewed against benchmark data from Dupixent studies, EP-104GI’s efficacy signals and potential once-yearly dosing profile appear highly competitive in a growing EoE market. In addition, the therapy has demonstrated a clean safety profile to date with no serious adverse events or steroid-related complications, and Eupraxia’s cash runway of more than 2.5 years supports execution of the upcoming Phase 2b trial and key value inflection points, together underpinning Slutsky’s constructive stance on the shares.
According to TipRanks, Slutsky is a top 100 analyst with an average return of 49.4% and a 54.74% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Spyre Therapeutics, and Enliven Therapeutics.